Belgian pharma company UCB (Euronext Brussels: UCB) has entered into a collaboration with Q-State Biosciences, an American firm, to discover new therapeutics.
The joint program will seek to develop novel drugs for epilepsy, and particularly genetically defined subtypes of childhood epilepsy that present with substantial morbidity, taking advantage of Q-State’s optogenetics platform.
UCB will provide research support, as well as prospective preclinical and clinical milestones and royalties. The companies have not disclosed financial terms, nor information on the genetic targets to be researched.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze